Show simple item record

A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin

dc.contributor.authorPectasides, Dimitriosen
dc.contributor.authorDafni, U.en
dc.contributor.authorAravantinos, Gerasimosen
dc.contributor.authorTimotheadou, E.en
dc.contributor.authorSkarlos, Dimosthenis V.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorGaglia, A.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorFountzilas, Georgeen
dc.creatorPectasides, Dimitriosen
dc.creatorDafni, U.en
dc.creatorAravantinos, Gerasimosen
dc.creatorTimotheadou, E.en
dc.creatorSkarlos, Dimosthenis V.en
dc.creatorPavlidis, Nicholasen
dc.creatorGaglia, A.en
dc.creatorKalofonos, H. P.en
dc.creatorFountzilas, Georgeen
dc.date.accessioned2018-06-22T09:54:23Z
dc.date.available2018-06-22T09:54:23Z
dc.date.issued2007
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42336
dc.description.abstractObjective: The objective of this study was to compare the efficacy of a disintegrating tablet of ondansetron (ODT) and the conventional tablet formulation of ondansetron (OT) in controlling nausea and vomiting in breast cancer patients. Patients and Methods: A total of 134 breast cancer patients receiving high-dose epirubicin participated in a randomized trial comparing the antiemetic efficacy and safety of an 8 mg OT given twice daily to an 8 mg orally ODT given twice daily, both for 3 days. Results: OT was significantly better in the complete control of emesis (72% versus 52%, p=0.020) and marginally better in the complete control of nausea (66% versus 48%, p=0.054) induced by high-dose epirubicin over days 1-3 compared to ODT. However, no differences were found in major control of emesis (0 to 2 emetic episodes, 76% versus 70%, p=0.28) over days 1-3. Conclusion: OT was significantly better in the complete control of emesis and marginally better in the complete control of nausea, but not in the major control of emesis and nausea induced by high-dose epirubicin compared to ODT. ODT may be an effective alternative to OT, particularly in patients who have difficulties in swallowing a conventional tablet.en
dc.language.isoengen
dc.sourceAnticancer Researchen
dc.subjectArticleen
dc.subjectCyclophosphamideen
dc.subjectFluorouracilen
dc.subjectHumanen
dc.subjectMethotrexateen
dc.subject80 and overen
dc.subjectAgeden
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBreast neoplasmsen
dc.subjectControlled studyen
dc.subjectFemaleen
dc.subjectMajor clinical studyen
dc.subjectMiddle ageden
dc.subjectPaclitaxelen
dc.subjectPriority journalen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectClinical trialen
dc.subjectControlled clinical trialen
dc.subjectDrug efficacyen
dc.subjectDrug safetyen
dc.subjectPhase 2 clinical trialen
dc.subjectDexamethasoneen
dc.subjectRandomized controlled trialen
dc.subjectTreatment outcomeen
dc.subjectDocetaxelen
dc.subjectOutcome assessmenten
dc.subjectDisease courseen
dc.subjectVomitingen
dc.subjectBreast canceren
dc.subjectDrug megadoseen
dc.subjectDisease severityen
dc.subjectMultiple cycle treatmenten
dc.subjectCombination chemotherapyen
dc.subjectUnspecified side effecten
dc.subjectEpirubicinen
dc.subjectAdjuvant therapyen
dc.subjectTreatment indicationen
dc.subjectAntiemeticsen
dc.subjectOndansetronen
dc.subjectBlood pressure measurementen
dc.subjectDrug formulationen
dc.subjectEmesisen
dc.subjectGeneric drugen
dc.subjectNauseaen
dc.subjectOrally disintegrating tableten
dc.subjectTablet disintegrationen
dc.subjectTablet formulationen
dc.subjectTabletsen
dc.titleA randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicinen
dc.typeinfo:eu-repo/semantics/article
dc.description.volume27
dc.description.issue6 Cen
dc.description.startingpage4411
dc.description.endingpage4417
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.contributor.orcidAravantinos, Gerasimos [0000-0002-2106-1713]
dc.contributor.orcidKalofonos, H. P. [0000-0002-3286-778X]
dc.gnosis.orcid0000-0002-2195-9961
dc.gnosis.orcid0000-0002-2106-1713
dc.gnosis.orcid0000-0002-3286-778X


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record